Cargando…

Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice

OBJECTIVES: This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. METHODS: Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to Ju...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Jun, Wang, Lingling, Zhou, Xin, Wang, Jing, Wang, Huan, Guo, Hongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023076/
https://www.ncbi.nlm.nih.gov/pubmed/29584537
http://dx.doi.org/10.1177/0300060518757640
_version_ 1783335789778698240
author Xia, Jun
Wang, Lingling
Zhou, Xin
Wang, Jing
Wang, Huan
Guo, Hongfeng
author_facet Xia, Jun
Wang, Lingling
Zhou, Xin
Wang, Jing
Wang, Huan
Guo, Hongfeng
author_sort Xia, Jun
collection PubMed
description OBJECTIVES: This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. METHODS: Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. RESULTS: EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM. The most common cause of death was infection (10/16, 62.5%). In the multivariate analysis, only an age of ≥75 years, International Staging System (ISS) stage III disease, and high lactate dehydrogenase concentration were significantly and independently associated with EM. CONCLUSION: Our results suggest that infection is the leading cause of EM in elderly patients with MM. An age of ≥75 years, ISS stage III disease, and a high lactate dehydrogenase concentration are significant predictors of EM. We should further target this higher-risk patient population to define personalized therapy with which to improve outcomes.
format Online
Article
Text
id pubmed-6023076
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60230762018-07-05 Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice Xia, Jun Wang, Lingling Zhou, Xin Wang, Jing Wang, Huan Guo, Hongfeng J Int Med Res Clinical Research Reports OBJECTIVES: This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. METHODS: Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. RESULTS: EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM. The most common cause of death was infection (10/16, 62.5%). In the multivariate analysis, only an age of ≥75 years, International Staging System (ISS) stage III disease, and high lactate dehydrogenase concentration were significantly and independently associated with EM. CONCLUSION: Our results suggest that infection is the leading cause of EM in elderly patients with MM. An age of ≥75 years, ISS stage III disease, and a high lactate dehydrogenase concentration are significant predictors of EM. We should further target this higher-risk patient population to define personalized therapy with which to improve outcomes. SAGE Publications 2018-03-27 2018-06 /pmc/articles/PMC6023076/ /pubmed/29584537 http://dx.doi.org/10.1177/0300060518757640 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Clinical Research Reports
Xia, Jun
Wang, Lingling
Zhou, Xin
Wang, Jing
Wang, Huan
Guo, Hongfeng
Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
title Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
title_full Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
title_fullStr Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
title_full_unstemmed Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
title_short Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
title_sort early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
topic Clinical Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023076/
https://www.ncbi.nlm.nih.gov/pubmed/29584537
http://dx.doi.org/10.1177/0300060518757640
work_keys_str_mv AT xiajun earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice
AT wanglingling earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice
AT zhouxin earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice
AT wangjing earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice
AT wanghuan earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice
AT guohongfeng earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice